

Company announcement no. 9-2018

Financial calendar 2019

ViroGates A/S (Nasdaq First North Denmark: VIRO) has published its financial calendar for 2019 with the following key dates:

| 20 March | Deadline for submission of business to be transacted at the 2019 Annual General Meeting |
|------------|---|
| 27 March | Annual Report 2018 |
| 25 April | Annual General Meeting |
| 29 April | Interim Report Q1 2019 |
| 29 July | Interim Report Q2 2019 |
| 28 October | Interim Report Q3 2019 |

The interim and annual financial reports will be available on Virogates' website <u>www.virogates.com</u> immediately after their release.

Written requests to have specific business transacted at the Annual General Meeting will be included in the agenda if received by the company no later than 20 March 2019 via email to <u>ik@virogates.com</u>

For further information please contact:

CEO Jakob Knudsen: Tel. (+45) 2113 1336, Email: jk@virogates.com

Certified Advisor

Västra Hamnen Corporate Finance, Per Lönn: Tel. (+46) 40 200 250, Email: per.lonn@vhcorp.se

About ViroGates

ViroGates is an international medtech company headquartered in Denmark. ViroGates develops and sells prognostic products to the healthcare sector. The products are used in hospital emergency services, in particular to make a clinical decision on hospitalization or discharge of emergency patients, which can lead to better clinical decisions, faster discharge and optimization of healthcare resources. The products can also be used for the prognosis of lifestyle-related diseases such as cardiovascular disease, type 2 diabetes, cancer, etc. The ViroGates test suPARnostic[®] measures the suPAR (Soluble urokinase Plasminogen Activator Receptor) protein in the bloodstream, and with the suPARnostic[®] Quick Triage test, hospital staff will get answers in just 20 minutes. The prognostic value of suPARnostic[®] is validated by more than 500 clinical trials and studies which included more than 350,000 blood samples.

